These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 33771716)

  • 1. Evaluation of the pharmacokinetic effects of itraconazole on alflutinib (AST2818): an open-label, single-center, single-sequence, two-period randomized study in healthy volunteers.
    Heng J; Tang Q; Chen X; Bao J; Deng J; Chen Y; Zhao J; Zhu S; Liu X; Yang F; Jiang Y; Yang N; Li K
    Eur J Pharm Sci; 2021 Jul; 162():105815. PubMed ID: 33771716
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of rifampicin on the pharmacokinetics of alflutinib, a selective third-generation EGFR kinase inhibitor, and its metabolite AST5902 in healthy volunteers.
    Zhu YT; Zhang YF; Jiang JF; Yang Y; Guo LX; Bao JJ; Zhong DF
    Invest New Drugs; 2021 Aug; 39(4):1011-1018. PubMed ID: 33506323
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Simultaneous determination of alflutinib and its active metabolite in human plasma using liquid chromatography-tandem mass spectrometry.
    Liu X; Li W; Zhang Y; Jiang Y; Zhao Q; Zhong D
    J Pharm Biomed Anal; 2019 Nov; 176():112735. PubMed ID: 31394305
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety, Clinical Activity, and Pharmacokinetics of Alflutinib (AST2818) in Patients With Advanced NSCLC With EGFR T790M Mutation.
    Shi Y; Zhang S; Hu X; Feng J; Ma Z; Zhou J; Yang N; Wu L; Liao W; Zhong D; Han X; Wang Z; Zhang X; Qin S; Ying K; Feng J; Fang J; Liu L; Jiang Y
    J Thorac Oncol; 2020 Jun; 15(6):1015-1026. PubMed ID: 32007598
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alflutinib (AST2818), primarily metabolized by CYP3A4, is a potent CYP3A4 inducer.
    Liu XY; Guo ZT; Chen ZD; Zhang YF; Zhou JL; Jiang Y; Zhao QY; Diao XX; Zhong DF
    Acta Pharmacol Sin; 2020 Oct; 41(10):1366-1376. PubMed ID: 32235864
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Randomized, Open, Single-Centre, Crossed Study of the Effect of Food on the Pharmacokinetics of One Oral Dose of Alflutinib Mesylate Tablets (AST2818) in Healthy Male Subjects.
    Zhu S; Deng J; Tang Q; Heng J; Qu J; Chen Y; Chen X; Yang N; Liu X; Li K
    Iran J Pharm Res; 2020; 19(3):24-33. PubMed ID: 33680007
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Study on pharmacokinetic interactions between SHR2554 and itraconazole in healthy subjects: A single-center, open-label phase I trial.
    Deng K; Zou Y; Zou C; Wang H; Xiang Y; Yang X; Yang S; Cui C; Yang G; Huang J
    Cancer Med; 2023 Jan; 12(2):1431-1440. PubMed ID: 35841331
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of Fluconazole and Itraconazole on the Pharmacokinetics of Erdafitinib in Healthy Adults: A Randomized, Open-Label, Drug-Drug Interaction Study.
    Poggesi I; Li LY; Jiao J; Hellemans P; Rasschaert F; de Zwart L; Snoeys J; De Meulder M; Mamidi RNVS; Ouellet D
    Eur J Drug Metab Pharmacokinet; 2020 Feb; 45(1):101-111. PubMed ID: 31673875
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An Open-Label Study to Assess the Effect of Itraconazole and Rifampin on Parsaclisib Pharmacokinetics When Administered Orally in Healthy Participants.
    Li J; Rockich K; Yuska B; Zhou G; Epstein N; Punwani N; Chen X; Yeleswaram S
    J Clin Pharmacol; 2020 Nov; 60(11):1519-1526. PubMed ID: 32515832
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of Cytochrome P450 3A4 Induction and Inhibition on the Pharmacokinetics of BI 425809, a Novel Glycine Transporter 1 Inhibitor.
    Desch M; Wunderlich G; Goettel M; Goetz S; Liesenfeld KH; Chan TS; Rosenbrock H; Sennewald R; Link J; Keller S; Wind S
    Eur J Drug Metab Pharmacokinet; 2022 Jan; 47(1):91-103. PubMed ID: 34716565
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Open-Label Assessment of the Effects of Itraconazole and Rifampicin on Balovaptan Pharmacokinetics in Healthy Volunteers.
    Derks MGM; Wandel C; Young A; Bolt SK; Meyenberg C
    Adv Ther; 2020 Nov; 37(11):4720-4729. PubMed ID: 32935287
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of Itraconazole and Rifampin on the Pharmacokinetics of Mobocertinib (TAK-788), an Oral Epidermal Growth Factor Receptor Inhibitor, in Healthy Volunteers.
    Zhang S; Jin S; Griffin C; Feng Z; Lin J; Venkatakrishnan K; Gupta N
    Clin Pharmacol Drug Dev; 2021 Sep; 10(9):1044-1053. PubMed ID: 34145979
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Furmonertinib (Alflutinib, AST2818) is a potential positive control drug comparable to rifampin for evaluation of CYP3A4 induction in sandwich-cultured primary human hepatocytes.
    Wu YL; Xue YR; Guo ZT; Chen ZD; Ge XY; Zhong DF; Diao XX
    Acta Pharmacol Sin; 2022 Mar; 43(3):747-756. PubMed ID: 34035488
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of Strong CYP2C8 or CYP3A Inhibition and CYP3A Induction on the Pharmacokinetics of Brigatinib, an Oral Anaplastic Lymphoma Kinase Inhibitor, in Healthy Volunteers.
    Tugnait M; Gupta N; Hanley MJ; Sonnichsen D; Kerstein D; Dorer DJ; Venkatakrishnan K; Narasimhan N
    Clin Pharmacol Drug Dev; 2020 Feb; 9(2):214-223. PubMed ID: 31287236
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Corrigendum to ' Evaluation of the pharmacokinetic effects of itraconazole on alflutinib (AST2818): an open-label, single-center, single-sequence, two-period randomized study in healthy volunteers'[European Journal of Pharmaceutical Sciences 162 (2021) 105815].
    Heng J; Tang Q; Chen X; Bao J; Deng J; Chen Y; Zhao J; Zhu S; Liu X; Yang F; Jiang Y; Yang N; Li K
    Eur J Pharm Sci; 2022 Apr; 171():106143. PubMed ID: 35181200
    [No Abstract]   [Full Text] [Related]  

  • 16. Effects of paroxetine, a CYP2D6 inhibitor, on the pharmacokinetic properties of hydrocodone after coadministration with a single-entity, once-daily, extended-release hydrocodone tablet.
    Kapil RP; Friedman K; Cipriano A; Michels G; Shet M; Mondal SA; Harris SC
    Clin Ther; 2015 Oct; 37(10):2286-96. PubMed ID: 26350273
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of autoinduction and food on the pharmacokinetics of furmonertinib and its active metabolite characterized by a population pharmacokinetic model.
    Zou HX; Zhang YF; Zhong DF; Jiang Y; Liu F; Zhao QY; Zuo Z; Zhang YF; Yan XY
    Acta Pharmacol Sin; 2022 Jul; 43(7):1865-1874. PubMed ID: 34789919
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy, safety, and genetic analysis of furmonertinib (AST2818) in patients with EGFR T790M mutated non-small-cell lung cancer: a phase 2b, multicentre, single-arm, open-label study.
    Shi Y; Hu X; Zhang S; Lv D; Wu L; Yu Q; Zhang Y; Liu L; Wang X; Cheng Y; Ma Z; Niu H; Wang D; Feng J; Huang C; Liu C; Zhao H; Li J; Zhang X; Jiang Y; Gu C
    Lancet Respir Med; 2021 Aug; 9(8):829-839. PubMed ID: 33780662
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The pharmacokinetics of pamiparib in the presence of a strong CYP3A inhibitor (itraconazole) and strong CYP3A inducer (rifampin) in patients with solid tumors: an open-label, parallel-group phase 1 study.
    Mu S; Lin C; Skrzypczyk-Ostaszewicz A; Bulat I; Maglakelidze M; Skarbova V; Andreu-Vieyra C; Sahasranaman S
    Cancer Chemother Pharmacol; 2021 Jul; 88(1):81-88. PubMed ID: 33772633
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Itraconazole and rifampicin, as CYP3A modulators but not P-gp modulators, affect the pharmacokinetics of almonertinib and active metabolite HAS-719 in healthy volunteers.
    Liu L; Li W; Yang L; Guo ZT; Xue H; Xie NJ; Chen XY
    Acta Pharmacol Sin; 2022 Apr; 43(4):1082-1090. PubMed ID: 34267345
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.